벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bracco imaging deutschland gmbh - gadotéridol 279,3 mg/ml - solution injectable - 279,3 mg/ml - gadotéridol 279.3 mg/ml - gadoteridol

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bracco imaging deutschland gmbh - gadotéridol 279,3 mg/ml - solution injectable - 279,3 mg/ml - gadotéridol 279.3 mg/ml - gadoteridol

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bracco imaging deutschland gmbh - gadotéridol 279,3 mg/ml - solution injectable - 279,3 mg/ml - gadotéridol 279.3 mg/ml - gadoteridol

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bracco imaging deutschland gmbh - gadotéridol 279,3 mg/ml - solution injectable - 279,3 mg/ml - gadotéridol 279.3 mg/ml - gadoteridol

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bracco imaging deutschland gmbh - gadotéridol 279,3 mg/ml - solution injectable - 279,3 mg/ml - gadotéridol 279.3 mg/ml - gadoteridol

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bracco imaging deutschland gmbh - gadotéridol 279,3 mg/ml - solution injectable - 279,3 mg/ml - gadotéridol 279.3 mg/ml - gadoteridol

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; trometamol; calteridol calcium - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of ge for enhancement of magnetic images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; calteridol calcium; trometamol; sodium hydroxide; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; calteridol calcium; trometamol; hydrochloric acid; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years ofage for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: trometamol; sodium hydroxide; calteridol calcium; water for injections; hydrochloric acid - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 yaers of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.